How Rezdiffra (Resmetirom) Affects Free T4 Levels

Why Resmetirom Lowers Free T4

Resmetirom is a liver-directed thyroid hormone receptor beta agonist. It selectively activates THR-β in hepatocytes without significant THR-α stimulation in the heart or bone. This selectivity is the entire pharmacologic rationale behind the drug.

The hypothalamic-pituitary-thyroid (HPT) axis responds to resmetirom's THR-β activation through a negative feedback loop. When hepatic THR-β signaling increases, the pituitary interprets this as adequate thyroid hormone activity and reduces TSH secretion slightly. Reduced TSH drive leads to decreased thyroidal T4 production, which manifests as a lower circulating Free T4 concentration 1.

This is not drug-induced hypothyroidism. The peripheral tissues still receive appropriate thyroid hormone signaling because resmetirom itself occupies the THR-β receptor in the liver. Think of it as the axis recalibrating around a new set point where exogenous THR-β agonism partially substitutes for endogenous T4-derived T3 action in hepatic tissue.

The distinction matters clinically. A physician unfamiliar with resmetirom's pharmacology might see a low Free T4 and initiate levothyroxine, which would be inappropriate in most cases. The FDA prescribing information for Rezdiffra specifically addresses thyroid function changes as an expected pharmacodynamic effect rather than an adverse event requiring intervention.

Magnitude and Time Course of Free T4 Changes

In the MAESTRO-NASH trial (N=966 randomized to resmetirom or placebo in the fibrosis resolution cohort), patients receiving resmetirom 80 mg experienced a mean Free T4 decrease of approximately 12% from baseline, while those on 100 mg showed reductions closer to 18% 1. These changes were dose-dependent and stabilized by week 12 in most participants.

The time course follows a predictable pattern. Free T4 begins declining within the first 2-4 weeks as the HPT axis adjusts. By week 8-12, a new steady state is typically reached. After 52 weeks of continuous therapy, Free T4 values remained stable at their new lower plateau without progressive decline 1.

Absolute values matter more than percentages. A patient starting with a Free T4 of 1.4 ng/dL who drops 18% lands at approximately 1.15 ng/dL, still within most laboratory reference ranges (0.8-1.8 ng/dL). Patients who begin treatment with Free T4 values already in the lower third of the reference range deserve closer monitoring because even a modest percentage drop could push them below the lower limit of normal.

The phase 3 data showed that fewer than 3% of resmetirom-treated patients developed Free T4 values below the lower limit of normal that persisted beyond a single measurement 1. Among those who did, most remained asymptomatic and did not require thyroid hormone replacement.

TSH Behavior During Resmetirom Treatment

TSH changes during resmetirom therapy are more nuanced than the Free T4 story. Most patients show stable or mildly decreased TSH values rather than the elevation you would expect in primary hypothyroidism.

This paradox confirms the central feedback mechanism. If the pituitary "sees" adequate THR-β activation (from resmetirom reaching pituitary thyrotrophs to some degree, or from the integrated systemic signal), it does not mount a compensatory TSH rise even as Free T4 falls. The result is a biochemical pattern that looks nothing like primary hypothyroidism (where TSH rises as T4 falls) and nothing like central hypothyroidism (where both fall due to pituitary disease) 2.

In MAESTRO-NASH, mean TSH values in the resmetirom groups decreased by approximately 0.3-0.5 mIU/L from baseline. No patients developed TSH suppression below 0.1 mIU/L attributable to study drug. This contrasts sharply with non-selective thyromimetics developed in the 2000s, which caused clinically significant TSH suppression and cardiac adverse effects due to THR-α cross-reactivity 2.

A rising TSH in a patient on resmetirom should prompt evaluation for intercurrent thyroid disease (autoimmune thyroiditis, iodine deficiency) rather than being attributed to the drug itself.

Who Needs Closer Thyroid Monitoring

Not every patient on resmetirom requires the same monitoring intensity. Several populations warrant more frequent Free T4 assessment.

Patients with pre-existing hypothyroidism on levothyroxine replacement present the most common clinical scenario requiring attention. Resmetirom's HPT axis effects could theoretically alter levothyroxine requirements, though the phase 3 data showed this was infrequent. The Endocrine Society recommends checking TSH and Free T4 6-8 weeks after any medication change that could affect thyroid economy 3.

Patients taking medications that affect thyroid hormone binding (estrogen therapy, tamoxifen, phenytoin, carbamazepine) may show amplified or attenuated Free T4 changes because these drugs alter the ratio of bound to free hormone independently of resmetirom's mechanism.

Elderly patients (age 75+) and those with cardiovascular disease deserve closer surveillance. Even mild thyroid function changes can affect cardiac output and heart rate in these populations. The MAESTRO-NASH trial included patients up to age 75, but real-world prescribing extends beyond trial demographics 1.

Patients with baseline Free T4 in the lower quartile of the reference range (0.8-1.0 ng/dL) should have repeat testing at 4 weeks rather than waiting the standard 12 weeks, as they have less margin before crossing below normal.

Differentiating Expected Changes from Pathology

The clinical challenge with resmetirom and Free T4 is distinguishing the drug's expected pharmacodynamic effect from new thyroid pathology that develops coincidentally during treatment.

Expected resmetirom effect looks like this: Free T4 decreases 10-20%, TSH stable or mildly decreased, patient asymptomatic, values stabilize by week 12. No intervention needed.

New primary hypothyroidism looks different: Free T4 decreases progressively beyond 20%, TSH rises above the upper limit of normal, patient develops fatigue or cold intolerance that worsens over time. This pattern warrants anti-TPO antibody testing and possible levothyroxine initiation regardless of resmetirom status 3.

Sick euthyroid syndrome (non-thyroidal illness) in a MASH patient with decompensating liver disease would show low Free T4, low or normal TSH, and low Free T3. This requires treating the underlying liver disease progression rather than adding thyroid hormone.

Dr. Stephen Harrison, principal investigator of MAESTRO-NASH, noted in the trial publication: "Thyroid function changes observed with resmetirom are consistent with its mechanism of action as a THR-β-selective agonist and were not associated with clinical hypothyroidism requiring treatment" 1.

Practical Monitoring Protocol

Based on the MAESTRO-NASH data and the FDA label, a reasonable monitoring approach for Free T4 during resmetirom therapy follows this schedule.

Before starting resmetirom: Obtain baseline TSH, Free T4, and Free T3. Document any pre-existing thyroid conditions and current thyroid medications. Patients with uncontrolled hypothyroidism (TSH >10 mIU/L) should have thyroid function optimized before initiating resmetirom 4.

Week 12: Repeat TSH and Free T4. Compare to baseline. If Free T4 has decreased <25% and remains within reference range with stable or decreased TSH, continue without intervention. Document the new values as the patient's "on-treatment baseline."

Every 6 months for year one: Recheck TSH and Free T4 to confirm stability at the new set point. After the first year, annual monitoring is sufficient in asymptomatic patients with stable values.

Unscheduled testing: Check thyroid function if the patient develops new symptoms suggesting hypothyroidism (unexplained weight gain exceeding 5 kg, persistent fatigue unrelated to liver disease, constipation, cold intolerance, bradycardia) or if other medications affecting thyroid binding are added or changed.

The American Association of Clinical Endocrinology (AACE) has not yet published specific guidance for monitoring thyroid function during resmetirom therapy, but their general thyroid monitoring recommendations provide a framework adaptable to this clinical scenario 5.

Free T4 vs. Total T4: Which Test to Order

Order Free T4, not Total T4, when monitoring patients on resmetirom. Total T4 includes protein-bound hormone that is metabolically inactive and is influenced by estrogen status, nutritional state, and hepatic synthetic function.

MASH patients frequently have altered hepatic protein synthesis, which affects thyroxine-binding globulin (TBG) production. A patient with advanced fibrosis may have lower TBG and therefore lower Total T4 independent of any resmetirom effect. Free T4 eliminates this confounding variable by measuring only the unbound, biologically available fraction 6.

The MAESTRO-NASH trial reported Free T4 as the primary thyroid function endpoint rather than Total T4, establishing it as the standard for clinical monitoring in this context 1.

If Free T4 results are borderline or discordant with clinical presentation, adding a Free T3 measurement provides additional information. Resmetirom's hepatic T3-mimetic activity means that tissue-level T3 signaling in the liver is maintained even when circulating thyroid hormone levels decrease. Serum Free T3 typically shows less change than Free T4 during resmetirom treatment because the drug's primary feedback effect operates through the T4-TSH axis.

Drug Interactions Affecting Thyroid Labs

Several medications commonly prescribed alongside resmetirom in the MASH population can independently affect Free T4 interpretation.

Biotin supplementation (common in patients with hair thinning from liver disease or weight loss) interferes with immunoassay-based Free T4 measurements, producing falsely elevated or decreased values depending on the assay platform. Patients should discontinue biotin for 48-72 hours before thyroid function testing 7.

GLP-1 receptor agonists, increasingly co-prescribed with resmetirom in patients with MASH and obesity, do not directly alter Free T4 but may affect TSH through weight-loss-mediated changes in thyroid hormone metabolism. A patient losing 15% body weight on semaglutide while simultaneously starting resmetirom may show larger Free T4 changes than expected from either drug alone.

Statins, used by over 60% of MASH patients for dyslipidemia, do not significantly interact with thyroid function testing. Resmetirom itself has lipid-lowering properties (LDL reduction of approximately 14% in MAESTRO-NASH) 1, which may allow statin dose reduction in some patients but does not create thyroid monitoring complications.

Proton pump inhibitors can reduce levothyroxine absorption in patients on thyroid replacement, potentially confounding interpretation if a patient on both levothyroxine and a PPI starts resmetirom and shows unexpected Free T4 changes.

What the MAESTRO-NASH Data Show

The MAESTRO-NASH trial, published in the New England Journal of Medicine in February 2024, randomized 966 patients with biopsy-confirmed MASH and stage F2 or F3 fibrosis to resmetirom 80 mg, resmetirom 100 mg, or placebo 1.

At 52 weeks, MASH resolution without worsening of fibrosis occurred in 25.9% of the 80 mg group and 29.9% of the 100 mg group, compared with 9.7% of the placebo group. Fibrosis improvement by at least one stage occurred in 24.2% (80 mg) and 25.9% (100 mg) versus 14.2% (placebo).

Regarding thyroid function specifically, the trial reported that resmetirom-treated patients showed expected decreases in Free T4 consistent with THR-β agonism. Discontinuation rates due to thyroid-related adverse events were low (<1%) and comparable between groups. No cases of myxedema or severe hypothyroidism were reported 1.

The Endocrine Society's guidelines on thyroid function testing note that interpretation of thyroid labs must account for medications that alter the HPT axis set point, placing resmetirom in a category alongside lithium, amiodarone, and immune checkpoint inhibitors as drugs requiring thyroid-aware prescribing 3.

When to Consider Levothyroxine Co-Prescription

Levothyroxine should not be reflexively added when Free T4 drops on resmetirom. The decision requires clinical correlation.

Consider levothyroxine only if all three criteria are met: Free T4 falls below the laboratory reference range, TSH rises above 10 mIU/L (or above 4.5 mIU/L with symptoms), and the patient has clinical manifestations of hypothyroidism that are not explained by their underlying liver disease or other comorbidities 3.

If levothyroxine is initiated, start at a low dose (25-50 mcg daily) and recheck in 6-8 weeks. The goal is not to restore Free T4 to the pre-resmetirom baseline but to relieve symptoms while maintaining the hepatic benefits of resmetirom therapy.

Resmetirom should not be discontinued solely because Free T4 has decreased, as long as the decrease follows the expected pattern and the patient is deriving hepatic benefit.

The baseline Free T4 value before initiating resmetirom at the standard dose of 100 mg (for patients weighing >100 kg) or 80 mg (for patients weighing ≤100 kg) serves as each patient's individual reference point for interpreting subsequent changes 4.